Intellia Therapeutics (NTLA) Accounts Payables (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Accounts Payables data on file, last reported at $18.8 million in Q1 2026.

• Quarterly Accounts Payables rose 52.05% year-over-year to $18.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.8 million (up 52.05% YoY) and the FY2025 annual result came in at $20.3 million, up 38.82% from the prior year.
• Accounts Payables slipped to $18.8 million in Q1 2026 per NTLA's latest filing, from $20.3 million in the prior quarter.
• Across five years, Accounts Payables topped out at $20.3 million in Q4 2025 and bottomed at $3.6 million in Q3 2023.
• The 5-year median for Accounts Payables is $11.6 million (2023), against an average of $11.3 million.
• The widest annual swing landed in 2024, when Accounts Payables surged 269.97%; it then plunged 47.91% in 2025.
• Tracing NTLA's Accounts Payables over 5 years: stood at $5.2 million in 2022, then surged by 44.59% to $7.5 million in 2023, then jumped by 95.77% to $14.6 million in 2024, then soared by 38.82% to $20.3 million in 2025, then declined by 7.17% to $18.8 million in 2026.
• Per Business Quant, the three latest NTLA Accounts Payables figures stand at $18.8 million (Q1 2026), $20.3 million (Q4 2025), and $13.3 million (Q3 2025).

Peer Comparison